Patients who have a history of heart disease but have stabilised now, benefit substantially when treated, with Ticagrelor. Often this is combined, with aspirin for additional advantages. The risk of episodes of newer ischemic attacks is greatly reduced using this therapy. However, the negative side is that the chances of bleeding increase over a period […]
Patients who have a history of heart disease but have stabilised now, benefit substantially when treated, with Ticagrelor. Often this is combined, with aspirin for additional advantages. The risk of episodes of newer ischemic attacks is greatly reduced using this therapy. However, the negative side is that the chances of bleeding increase over a period of time after regular consumption of this drug.
After about a year after being treated, with dual anti platelet ticagrelor, the chances of a stroke or death from cardio vascular disease is substantially reduced as compared to being treated, with aspirin alone as was formerly the case. Medical research has shown that the best dose that is best tolerated by the body is 60 mg. of ticagrelor and aspirin taken twice daily. This also helped in case of bleeding.
Advanced scientific studies conducted by PEGASUS in San Diego’s American College of Cardiology, clearly emphasized the need to use the exact amount of ticagrelor. Pharmaceutical major, Astra Zeneca, conducted an extensive trial on more than 21,000 patients in January, emphasizing the benefits of ticagrelor consumed in the right amount. They proceeded to make their case stronger by endorsing the fact that ticagrelor prevented the onset of future heart disease.
The Henry Ford Hospital in Detroit conducted their own research called “PLATO” wherein they concluded that surprisingly patients in Europe who were treated, with ticagrelor responded much more positively than those that there were treated in the United States. This diversity baffled the medical community and has now asked research sources to find out the reason for this disparity.
About 10,000 patients, with myocardial infarction were treated with 60 mg dose of ticagrelor in another experiment. This revealed that only 33 patients showed signs of bleeding as against patients who took higher doses of the drug. This study also showed that longer usage of ticagrelor (about 3 years) showed much better results, confirming the fact that it must be had for extended periods of time.
Leave a Reply